Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
...
BET Inhibitors (Bromodomain Inhibitors) for Neurodegenerative Diseases
Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Mermaid diagram (expand to render)
BET (bromodomain and extra-terminal) inhibitors are a class of epigenetic drugs that block the binding of BET proteins to acetylated histone residues. By inhibiting BET proteins, these compounds prevent the transcription of pro-inflammatory genes and can modulate protein aggregation pathways relevant to neurodegenerative diseases. [@bet2019]
Mechanism of Action
BET inhibitors exert neuroprotective effects through multiple mechanisms:
Transcriptional Suppression: BET proteins are readers of histone acetylation that recruit transcriptional co-activators. Inhibiting BET proteins suppresses expression of inflammatory genes including [NF-κB](/entities/nf-kb) target genes.
[α-Synuclein](/proteins/alpha-synuclein) Regulation: BET inhibitors reduce α-synuclein expression at the transcriptional level by affecting the SNCA gene promoter.
[Tau](/proteins/tau) Pathology: BRD4 regulates [tau](/proteins/tau) expression and alternative splicing; BET inhibitors reduce tau burden in models.
Neuroinflammation: Strong anti-inflammatory effects in [microglia](/entities/microglia) and [astrocytes](/entities/astrocytes).
[Autophagy](/entities/autophagy) Induction: Some BET inhibitors activate transcription factor EB (TFEB), enhancing autophagy and lysosomal biogenesis.
Key Drug Candidates
First-Generation BET Inhibitors
JQ1: Prototype BET inhibitor; extensively studied in neurodegeneration models; shows neuroprotection in AD, PD, HD models
I-BET151 (GSK1210151A): Preclinical studies in PD and HD models
I-BET762 (GSK525762): In clinical trials for cancer; preclinical neuroprotection
The study of Bet Inhibitors (Bromodomain Inhibitors) For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
References
[^1] Nocturne G, et al, BET protein inhibition reduces alpha-synuclein pathology in Parkinson's disease models (2020)
[^2] Yin Z, et al, JQ1, a BET inhibitor, attenuates tau pathology and cognitive deficits in Alzheimer's disease models (2018)
[^3] T. Shioda et al., BET inhibitor JQ1 modulates mutant huntingtin expression and pathology in Huntington's disease models. Proc Natl Acad Sci USA. 2016;113(52):10488-10497 (2016)
[^4] Wu M, et al, I-BET151 protects dopaminergic neurons from neurotoxicity via autophagy regulation (2021)
[^5] Liu Y, et al, BRD4 regulates neuroinflammation in Alzheimer's disease via NF-κB signaling (2022)
[^6] Park G, et al, BET inhibitors attenuate microglial activation and ameliorate cognitive deficits in AD models (2021)
[^7] Cheng J, et al, BRD4 regulates alternative splicing of tau in Alzheimer's disease (2021)
[^8] H. Zhang et al., BET inhibition as a therapeutic strategy for ALS. Ann Neurol. 2019;86(4):519-531 (2019)